Tumor News and Research

RSS

EORTC study does not support combination chemotherapy for soft tissue sarcoma

An EORTC study published in The Lancet Oncology does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma, unless the objective is to shrink the tumor.

27 Mar 2014

Study: Dab2 can exhibit neuroprotective effects in Alzheimer's by regulating TGF-β1/SMAD signaling

Transforming growth factor-beta (TGF-β) type II receptor (TβRII) levels are extremely low in the brain tissue of patients with Alzheimer's disease.

27 Mar 2014

Shimadzu announces FDA approval for new digital angiography systems

Shimadzu Medical Systems USA has announced that a new digital angiography system family has received 510(k) clearance from the U.S. Food and Drug Administration. These are the ceiling-mounted Trinias, the floor-mounted Trinias, and the Biplane models.

27 Mar 2014

FDA grants PMA for Pinnacle's Optiguide DCYL700 Fiber Optic Diffuser Series flexible fiber

Concordia Healthcare Corp. announced today that its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, was granted U.S. Food and Drug Administration premarket supplemental approval (PMA) for its Optiguide DCYL700 Fiber Optic Diffuser Series flexible fiber.

26 Mar 2014

Patients with genetic variants are likely to experience bladder cancer recurrence

In the Western world, bladder cancer is the fourth most common cancer in men and the eighth most common in women, with many patients experiencing recurrence after treatment.

26 Mar 2014

European Commission approves Exelixis' COMETRIQ for treatment of progressive, metastatic MTC

Exelixis, Inc. today announced that the European Commission has approved COMETRIQ (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC).

25 Mar 2014

Radiation therapy fights cancer in more ways than one

Radiation therapy fights cancer in more ways than one. Not only does it force cancer cells to self-destruct, but several studies demonstrate that it also activates the immune system to attack tumor cells.

25 Mar 2014

XBP1 gene plays pivotal role in the growth and progression of triple negative breast cancer

Scientists from Weill Cornell Medical College and Houston Methodist have found that a gene previously unassociated with breast cancer plays a pivotal role in the growth and progression of the triple negative form of the disease, a particularly deadly strain that often has few treatment options. Their research, published in this week's Nature, suggests that targeting the gene may be a new approach to treating the disease.

25 Mar 2014

Researchers develop one-step analysis for detecting tumor markers in blood

Benign growth, or cancer? Tumor markers in the blood help determine whether the patient is afflicted with a malign tumor and whether it is excreting markers more vigorously - involving highly specific proteins. An increased concentration in the blood provides one indication of the disease for physicians. However, it has been quite expensive in time and effort to detect the markers thus far. This is because all kinds of molecules and proteins are teeming in the blood. To be able to detect a single specific one, doctors must first separate and purify the blood in several steps, and then isolate the marker they are searching for from the rest of the molecules.

25 Mar 2014

Agios initiates AG-120 Phase 1 study to evaluate advanced solid tumors with IDH1 mutation

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced dose administration for the first patient in a Phase 1 study of AG-120 in patients with advanced solid tumors with an isocitrate dehydrogenase-1 (IDH1) mutation.

25 Mar 2014

Study uncovers one way that p53 acts to prevent cancer cell invasion

The tumor suppressor p53 does all it can to prevent oncogenes from transforming normal cells into tumor cells by killing defective cells or causing them to become inactive.

25 Mar 2014

Not all doctors offer cancer gene testing to patients, study finds

Many cancer researchers believe that cutting-edge advances in genomics will pave the way for personalized or "precision" cancer medicine for all patients in the near future. A new study by researchers at Dana-Farber Cancer Institute, however, suggest that not all doctors are ready to embrace tests that look for hundreds of DNA changes in patients' tumor samples, while others plan to offer this type of cancer gene testing to most of their patients.

25 Mar 2014

Scientist receives $275,000 grant to study human papillomavirus that causes head and neck cancer

Basic scientists focus on understanding how things work, so most don't get the chance to directly impact other people's lives. That's why Michelle Ozbun, PhD, is very excited about her recent grant to study human papillomavirus.

25 Mar 2014

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a pivotal global Phase 3 clinical trial to evaluate the efficacy and safety of aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma (STS) under a Special Protocol Assessment with the FDA.

25 Mar 2014

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.

24 Mar 2014

New method can identify cancer's visible precursors with 97% certainty

Pancreatic cancer is often detected at a late stage, which results in poor prognosis and limited treatment options. Researchers at The University od Gothenburg, Sweden, have now developed a method which identifies the cancer's visible precursors with 97% certainty. The method, which is expected to aid in the early discovery of the cancer as well as minimize the risk of unnecessary surgery, may be introduced in patient care within five years.

24 Mar 2014

New insight into germline EGFR T790M mutation in familial non-small cell lung cancer

Two studies are providing new insight into germline epidermal growth factor receptor (EGFR) T790M mutation in familial non-small cell lung cancer (NSCLC). The findings suggest the need for tailored approaches for early detection and treatment, as well as for genetic testing to identify carriers.

24 Mar 2014

CUMC researchers devise new system for classifying periodontal disease

Researchers at Columbia University Medical Center have devised a new system for classifying periodontal disease based on the genetic signature of affected tissue, rather than on clinical signs and symptoms. The new classification system, the first of its kind, may allow for earlier detection and more individualized treatment of severe periodontitis, before loss of teeth and supportive bone occurs.

24 Mar 2014

Measuring circulating tumor cells may help better predict prostate cancer survival

New research by USC Norris Comprehensive Cancer Center scientists demonstrates that measuring circulating tumor cells (CTCs) - the cells that spread cancer through the body - may be a better predictor of patient survival than the prostate specific antigen (PSA).

24 Mar 2014

Bariatric surgery reduces uterine cancer risk by 71%

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center report that bariatric surgery resulting in dramatic weight loss in formerly severely obese women reduces the risk of endometrial (uterine) cancer by 71 percent and as much as 81 percent if normal weight is maintained after surgery.

24 Mar 2014

Tumor News and Research

EORTC study does not support combination chemotherapy for soft tissue sarcoma

Study: Dab2 can exhibit neuroprotective effects in Alzheimer's by regulating TGF-β1/SMAD signaling

Shimadzu announces FDA approval for new digital angiography systems

FDA grants PMA for Pinnacle's Optiguide DCYL700 Fiber Optic Diffuser Series flexible fiber

Patients with genetic variants are likely to experience bladder cancer recurrence

European Commission approves Exelixis' COMETRIQ for treatment of progressive, metastatic MTC

Radiation therapy fights cancer in more ways than one

XBP1 gene plays pivotal role in the growth and progression of triple negative breast cancer

Researchers develop one-step analysis for detecting tumor markers in blood

Agios initiates AG-120 Phase 1 study to evaluate advanced solid tumors with IDH1 mutation

Study uncovers one way that p53 acts to prevent cancer cell invasion

Not all doctors offer cancer gene testing to patients, study finds

Scientist receives $275,000 grant to study human papillomavirus that causes head and neck cancer

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

New method can identify cancer's visible precursors with 97% certainty

New insight into germline EGFR T790M mutation in familial non-small cell lung cancer

CUMC researchers devise new system for classifying periodontal disease

Measuring circulating tumor cells may help better predict prostate cancer survival

Bariatric surgery reduces uterine cancer risk by 71%

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News